Immuron (IMRN) Stock Price, News & Analysis

Company Overview

Immuron Limited (NASDAQ:IMRN) is an Australian biopharmaceutical company focused on developing and commercializing orally delivered immunotherapies. Its products are based primarily on antibodies derived from hyperimmune bovine colostrum and are designed to act locally in the gastrointestinal tract rather than enter the bloodstream.

The company’s leading product is Travelan, an oral treatment intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC). Travelan has been marketed in several countries, including the United States, Canada, and Australia, subject to the regulatory status and labeling requirements in each jurisdiction.

Immuron also conducts research on additional oral antibody-based therapies for gastrointestinal and infectious diseases. Its development programs have included candidates such as IMM-124E and IMM-529, which have been investigated for potential applications involving gastrointestinal disorders and infections. The company is headquartered in Melbourne, Australia, and serves international markets through regulatory, commercial, and distribution activities.

Key Stats

• Today's Range: $0.95 to $1.04
• 50-Day Range: $0.98 to $1.84
• 52-Week Range: $0.68 to $2.35
• Volume: 21,374 shs
• Average Volume: 74,466 shs
• Market Capitalization: $7.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Immuron Stock Analysis - MarketRank™

Immuron scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Immuron has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Immuron has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Immuron has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.82% of the float of Immuron has been sold short.

Short Interest Ratio / Days to Cover

Immuron has a short interest ratio ("days to cover") of 0.56, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Immuron has recently decreased by 46.62%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immuron does not currently pay a dividend.

Dividend Growth

Immuron does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.66

News Sentiment

Immuron has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Immuron this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immuron insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.01% of the stock of Immuron is held by insiders.

Percentage Held by Institutions

0.12% of the stock of Immuron is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/16/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMRN
• CIK: 1660046
• Web: www.immuron.com.au
• Phone: (138) 892-4854
• Fax: 6103 98227735
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.26
• Quick Ratio: 5.98

Sales & Book Value

• Annual Sales: $5.47 million
• Price / Sales: 1.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.94 per share
• Price / Book: 1.04

Miscellaneous

• Outstanding Shares: 8,070,000
• Free Float: 7,505,000
• Market Cap: $7.93 million
• Optionable: Not Optionable
• Beta: 1.09